Rituximab in refractory myasthenia gravis: a prospective, open‐label study with long‐term follow‐up
Author:
Affiliation:
1. Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada T6G 2G3
Publisher
Wiley
Subject
Clinical Neurology,General Neuroscience
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.314
Reference11 articles.
1. Myasthenia gravis: subgroup classification and therapeutic strategies
2. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
3. Rituximab for myasthenia gravis
4. Rituximab in the management of refractory myasthenia gravis
5. Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study
Cited by 73 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis;Journal of Neurology;2024-06-05
2. Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities;Frontiers in Pharmacology;2024-05-27
3. Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov;Scientific Reports;2024-01-24
4. Effects of acupuncture treatment for myasthenia gravis: A systematic review and meta-analysis;PLOS ONE;2024-01-02
5. Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysis;Frontiers in Neurology;2023-12-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3